drugset / Trial / NCT05205200
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Phase 2
Recruiting
338 enrolled
Fudan University
Affiliated Hospital of Nantong University · collabChongqing University Cancer Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Hospital of China Medical University · collabFujian Medical University Union Hospital · collabLiaoning Cancer Hospital & Institute · collabNingbo Medical Center Lihuili Hospital · collabNorthern Jiangsu People's Hospital · collabPeking University Cancer Hospital & Institute · collabShanghai 6th People's Hospital · collabShanghai First Maternity and Infant Hospital · collabSun Yat-sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Timeline
- Start
- 2022-06-06
- Primary completion
- 2025-02-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Dalpiciclib | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |